Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zhejiang East-Asia Pharmaceutical Co's EV-to-EBIT for today is
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-92 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA for today is:
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-92 Mil.
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,014 Mil.
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-102 Mil.
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil.
Zhejiang East-Asia Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-151 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co Enterprise Value Related Terms
Zhejiang East-Asia Pharmaceutical Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co Enterprise Value Chart
SHSE:605177 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Enterprise Value falls into.
Zhejiang East-Asia Pharmaceutical Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Enterprise Value of ¥2,370 Mil as of Jul. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors.
Is Zhejiang East-Asia Pharmaceutical Co's Enterprise Value too high?
Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Enterprise Value compare to VRTX and REGN?
Zhejiang East-Asia Pharmaceutical Co's Enterprise Value of ¥2,370 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,370 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current Enterprise Value is ¥2,370 Mil. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Enterprise Value is ¥2,370 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
Enterprise Value: ¥2,370 Mil
GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Business Description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
57GF Score
Get the complete analysis for SHSE:605177
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
